Thermoplastic polymers are defined as a unique group of polymers whose structure can be softened / melted under the application of heat and are then returns to its original state under cooling environment. On the other hand, thermoplastic elastomers (TPE) are defined as thermoplastics that possess the characteristics of rubber but are manufactured without the process of vulcanization. In fact, TPEs are processed with by using plastic manufacturing equipment such as, injection molding, blow moldi

As per the data published by Centers for Disease Control and Prevention (CDC) in December 2022, oncological disorders (various types of cancer) have emerged as the second leading cause of death in the US. In fact, as per recent studies, the annual burden of oncological disorders is more than USD 185 billion in the US. In order to address the aforementioned challenge, various developers across the globe, have identified inhibition of enhancer of zeste homolog 2 (EZH2) as one of the potential targ

Orthokeratology is defined as the use of custom designed (as per the patient’s needs) and fitted contact lenses that are used to improve vision. This is achieved by temporarily reshaping the patient’s cornea. Majority of these novel ortho-k lenses are worn at night, during the sleep cycle, to reshape the front surface of the eye. It is worth highlighting that the United States Food and Drug Administration (USFDA) has recently stated that ortho-k lenses are safe for use by patients be

The “Bullous Pemphigoid: Pipeline Review, Developer Landscape and Competitive Insights, 2022-2035” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Bullous Pemphigoid.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elem

The “Dry Age-related Macular Degeneration: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Dry Age-related Macular Degeneration.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual

The “Cushing’s Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cushing’s Syndrome.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition t

The “Idiopathic Short Stature: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Idiopathic Short Stature.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition t

The “Chronic Inflammatory Demyelinating Polyneuropathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market shar

The “Familial Amyloid Polyneuropathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Familial Amyloid Polyneuropathy. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In ad

The “X-linked Hypophosphatemia: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of X-linked Hypophosphatemia.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition

The “Tumor-induced Osteomalacia: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Tumor-induced Osteomalacia.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In additi

The “Hidradenitis Suppurativa: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Hidradenitis Suppurativa. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to othe

The “Amblyopia: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Amblyopia. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes

The “Chronic Cough: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Chronic Cough. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study

The “Refractory Gout: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Refractory Gout.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements,

The “C3 Glomerulopathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of C3 Glomerulopathy.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elemen

The “Angiomatosis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Angiomatosis.   This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the st

The “Giant Cell Arteritis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Giant Cell Arteritis. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elemen

The “Plexiform Neurofibroma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Plexiform Neurofibroma. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other el

The “Spinocerebellar Ataxias: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Spinocerebellar Ataxias. This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other